News

In this final interview of a three-part video series, Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, told MHE, in response to our recent annual Pharmacy Survey results, that FDA drug approval delays due to government cuts are happening but not widespread yet. He added that early signs and staffing challenges suggest the situation could worsen over time.

Value-based healthcare programs are mostly used in rich countries and usually only in small parts of health systems. According to a study published in JAMA Health Forum, these tools can be harder to implement because of system problems, not enough long-term information and lack of research in low-income countries.

GLP-1s are the main reason why pharmacy expenditures have reached double digits in 2025, a continuing trend from 2024, according to Eric Tichy, Pharm.D., M.B.A., vice chair of pharmacy formulary at the Mayo Clinic Health System.

Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, shared his insights on the results of Managed Healthcare Executive’s annual Pharmacy Survey in this part-two interview of a three-video series. In the interview, he discussed survey respondents’ views on Alzheimer’s disease as a leading driver of rising U.S. drug spending over the next three years. More than 100 healthcare industry experts took part in this year’s survey.

In this first of a three-part video interview series, Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, shared his input on Managed Healthcare Executive’s annual Pharmacy Survey results. In this interview, he gave his thoughts on respondents’ answers regarding new treatments that are most likely to significantly impact payer budgets this year and early next. Over 100 healthcare industry experts participated in this year’s survey.

Eric Tichy, Pharm.D., M.B.A., vice chair of pharmacy formulary at the Mayo Clinic Health System, explains potential pharmaceutical spending trends to inform the budgets of health system leaders.

Here’s what you missed this week on Managed Healthcare Executive.

Alli Oakes, executive director of research at Trilliant Health, shared that upcoding is a “prime example” of healthcare waste—where visits are billed at increasing levels of intensity without clinical justification.

Zynyz is now FDA-approved as the first and only approved first line treatment for advanced squamous cell carcinoma of the anal canal.

Self-collected samples to test for cervical cancer are a step in the right direction when it comes to addressing healthcare barriers, according to Rahma S. Mkuu, Ph.D., M.P.H., assistant professor in the Department of Health Outcomes & Biomedical Informatics at the University of Florida College of Medicine.

During a hearing, senators asked HHS Secretary Robert F. Kennedy Jr. to explain the rationale for the reorganization changes the agency has made since he was confirmed.

There are several ways to address HIV in homeless populations, with the most promising being the low barrier care model, according to Julie Dombrowski, M.D., M.P.H., professor of medicine at the University of Washington and director of HIV treatment initiatives at the King County, Seattle public health department.

In a Q&A with Leanne Berge, J.D., CEO of Community Health Plan of Washington, Berge explains what the newly proposed Medicaid bill would mean for enrollees and healthcare systems if passed.

A Republican-led bill aiming to tighten Medicaid eligibility and impose work requirements sparked heated protests and clashes amongst House parties, with critics warning it could leave millions without health coverage.

Their concerns come in response to the bill unveiled Sunday night by House Republicans that would tighten eligibility rules, create work requirements and freeze provider taxes under Medicaid—the federal-state program that insures nearly 80 million low-income Americans.

Homelessness and HIV share common risk factors, according to Julie Dombrowski, M.D., M.P.H., professor of medicine at the University of Washington and director of HIV treatment initiatives at the King County, Seattle public health department.

Industry leaders and policy experts have said President Trump’s executive order on Most Favored Drug Pricing is flawed and ignores the basic economics of the global drug marketplace.

The House Energy and Commerce Committee has scheduled a public markup hearing for the Republican bill for tomorrow at 2 p.m.

In a press conference, President Donald J. Trump announced that he would sign an executive order that ties drug pricing to prices in other developed countries. He also vowed to cut out the “middlemen” to bring the new prices to American citizens.

A new survey by Johnson & Johnson revealed that oncologists are overwhelmed by the rapid pace of innovation in cancer care, with many calling for better tools, education and collaboration to help integrate new treatments and technologies into everyday practice.

Here’s what you missed this week on Managed Healthcare Executive.

While providers do bring up menopause with patients during visits, there are still some knowledge gaps, according to the results of a recent survey of women ages 40 to 70 and healthcare providers.

In a conversation with Managed Healthcare Executive, 10XBeta CEO Marcel Botha warned that proposed Medicaid cuts, combined with federal budget reductions under the DOGE initiative, could exacerbate the rural healthcare crisis—threatening efforts to bring mobile, community-driven innovations to underserved areas.

Previously used to treat HIV and Hepatitis B, nucleoside reverse transcriptase inhibitors (NRTIs) reduced the risk of Alzheimer’s disease by an average of 9% every year, according to new research published in Alzheimer’s and Dementia.

An overview of endometriosis subtypes, treatment options and costs, according to a recent research review published in JAMA.

Researchers are exploring the topic of "time toxicity" — how much time patients spend receiving care. This study is the first to directly compare time spent in care between clinical trial participants and routine care patients receiving the same treatments.

John Levine, M.D., a graft-versus-host-disease expert at the Icahn School of Medicine at Mount Sinai in New York, makes a case for biomarkers in a review article published in the American Journal of Hematology.

The FDA has accepted the new drug application for the antipsychotic Bysanti and set a goal date for February 21, 2026.